Virtus LifeSci Biotech Clinical Trials ETF (BBC)Health | Exchange Traded Fund | NYSEArca
40.64 USD
-2.42
(-5.615%) ⇩
(Oct. 13, 2026, 3:59 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:08 a.m. EDT
The clinical trials biotech sector is currently in a precarious holding pattern for this ETF. While the underlying business quality shows resilience with a positive multi-year trajectory and no recent consecutive declines, the market has punished the asset heavily, leaving it trading well below its 52-week highs. The recent price action reveals a distinct lack of momentum; the stock has failed to reclaim key moving averages, and the trailing 14-day performance is flat-to-negative, erasing earlier gains. Crucially, the options market offers no relief, with speculative capital largely absent and put buyers positioning for continued stagnation or a drop. The dividend yield, while present, is insufficient to offset the capital destruction risk inherent in a sector facing regulatory headwinds and funding constraints. Until there is a clear reversal in price momentum or a surge in speculative call activity, this remains a neutral hold where the odds favor waiting for a better entry point rather than adding to the position. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.051251 |
| AutoTheta | 0.052135 |
| AutoETS | 0.052509 |
| AutoARIMA | 0.052509 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 1.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.291 |
| Excess Kurtosis | -0.69 |
As of Oct. 10, 2026, 7:08 a.m. EDT: Speculator positioning is extremely thin and fragmented across expirations, indicating a lack of consensus on immediate direction. Call volume is negligible, while put interest is concentrated in the near term (October 2026) at strikes below the current price, suggesting a defensive hedge against further downside rather than a bet on a rally. Implied volatility remains low, reflecting muted expectations for significant moves.
| Last Yield | 1yr Yield | 3yr Avg | 5yr Avg |
|---|---|---|---|
| 1.63% | 1.63% | 1.00% | 0.60% |
| Date | Dividend | Yield % |
|---|---|---|
| 2025-12-22 | 0.655 | 1.630164 |
| 2024-12-20 | 0.240 | 0.986518 |
| 2023-12-20 | 0.082 | 0.368705 |
| 2017-12-20 | 0.297 | 1.084337 |
| 2015-12-21 | 0.147 | 0.504288 |
| Attribute | Value |
|---|---|
| All Time High | 62.6 |
| All Time Low | 13.42 |
| Ask | 0.0 |
| Ask Size | 900 |
| Average Daily Volume10 Day | 15,890 |
| Average Daily Volume3 Month | 18,093 |
| Average Volume | 18,093 |
| Average Volume10Days | 15,890 |
| Beta3 Year | 1.2 |
| Bid | 0.0 |
| Bid Size | 300 |
| Category | Health |
| Crypto Tradeable | 0 |
| Currency | USD |
| Custom Price Alert Confidence | HIGH |
| Day High | 42.51 |
| Day Low | 40.64 |
| Display Name | LifeSci Biotech Clinical ETF |
| Dividend Date | 1,514,332,800 |
| Dividend Yield | 1.42 |
| Esg Populated | 0 |
| Exchange | PCX |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 50.09368 |
| Fifty Day Average Change | -9.453682 |
| Fifty Day Average Change Percent | -0.18872005 |
| Fifty Two Week Change Percent | 40.464546 |
| Fifty Two Week High | 56.18 |
| Fifty Two Week High Change | -15.540001 |
| Fifty Two Week High Change Percent | -0.2766109 |
| Fifty Two Week Low | 28.725 |
| Fifty Two Week Low Change | 11.914999 |
| Fifty Two Week Low Change Percent | 0.41479543 |
| Fifty Two Week Range | 28.725 - 56.18 |
| First Trade Date Milliseconds | 1,418,826,600,000 |
| Five Year Average Return | -0.0033149999 |
| Full Exchange Name | NYSEArca |
| Fullday Change | -2.3824997 |
| Fullday Change Percent | -5.533298 |
| Fullday Price | 40.64 |
| Fund Family | Virtus |
| Fund Inception Date | 1,418,688,000 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Has Pre Post Market Data | 1 |
| Language | en-US |
| Legal Type | Exchange Traded Fund |
| Long Business Summary | Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. |
| Long Name | Virtus LifeSci Biotech Clinical Trials ETF |
| Market | us_market |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_274653436 |
| Nav Price | 43.03343 |
| Net Assets | 43,834,060.0 |
| Net Expense Ratio | 0.65 |
| Open | 42.51 |
| Phone | (212) 593-4383 |
| Previous Close | 43.0575 |
| Price Hint | 2 |
| Quote Source Name | Delayed Quote |
| Quote Type | ETF |
| Region | US |
| Regular Market Change | -2.4175 |
| Regular Market Change Percent | -5.61458 |
| Regular Market Day High | 42.51 |
| Regular Market Day Low | 40.64 |
| Regular Market Day Range | 40.64 - 42.51 |
| Regular Market Open | 42.51 |
| Regular Market Previous Close | 43.0575 |
| Regular Market Price | 40.64 |
| Regular Market Time | 1,791,921,592 |
| Regular Market Volume | 52,877 |
| Short Name | Virtus Biotech Clinical Trials |
| Source Interval | 15 |
| Symbol | BBC |
| Three Year Average Return | 0.34233218 |
| Total Assets | 43,834,060 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Trailing Three Month Nav Returns | -12.41012 |
| Trailing Three Month Returns | -12.41012 |
| Triggerable | 1 |
| Two Hundred Day Average | 45.4463 |
| Two Hundred Day Average Change | -4.806301 |
| Two Hundred Day Average Change Percent | -0.10575781 |
| Type Disp | ETF |
| Volume | 52,877 |
| Yield | 0.014199999 |
| Ytd Return | 19.28414 |